ReviewJournal of clinical and experimental hepatology
Magnitude of Nonalcoholic Fatty Liver Disease: Western Perspective.
Review in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Chronic liver disease is an important risk factor for worse outcomes in acute pancreatitis: a systematic review and meta-analysis.Scientific reports · 2024Pooled it
- Effects of Time-Restricted Eating on Nonalcoholic Fatty Liver Disease: The TREATY-FLD Randomized Clinical Trial.JAMA network open · 2023Trial
- Article
- Metabolic dysregulation in MASLD-associated HCC: diagnostic biomarkers and therapeutic opportunities.Frontiers in medicine · 2025Review
- Sex differences in diet-induced MASLD - are female mice naturally protected?Frontiers in endocrinology · 2025Article
- Dihydromyricetin Alleviates Non-Alcoholic Fatty Liver Disease by Modulating Gut Microbiota and Inflammatory Signaling Pathways.Journal of microbiology and biotechnology · 2024Article
- Performance of ATT and UDFF in the diagnosis of non-alcoholic fatty liver: An animal experiment.Heliyon · 2024Article
- Rosae multiflorae fructus regulates the lipogenesis in high-fat diet-induced NAFLD mice model.Physical activity and nutrition · 2023Article
- Deep Learning-Based Image Analysis of Liver Steatosis in Mouse Models.The American journal of pathology · 2023Article
- Regional and National Trends of Adult Living Donor Liver Transplantation in the United States Over the Last Two Decades.Journal of clinical and translational hepatology · 2022Article
- The association of pericardial fat and peri-aortic fat with severity of nonalcoholic fatty liver disease.Scientific reports · 2022Article
- Pericardial fat, thoracic peri-aortic adipose tissue, and systemic inflammatory marker in nonalcoholic fatty liver and abdominal obesity phenotype.Scientific reports · 2022Article
- Association of Subclinical Hypothyroidism with Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study.Advanced biomedical research · 2022Article
- Gender-Based Association of Coronary Artery Calcification and Framingham Risk Score With Non-alcoholic Fatty Liver Disease and Abdominal Obesity in Taiwanese Adults, a Cross-Sectional Study.Frontiers in cardiovascular medicine · 2022Article
- A New Score Unveils a High Prevalence of Mild Cognitive Impairment in Patients with Nonalcoholic Fatty Liver Disease.Journal of clinical medicine · 2021Article
- Liver fat storage is controlled by HNF4α through induction of lipophagy and is reversed by a potent HNF4α agonist.Cell death & disease · 2021Article
- Dietary Patterns and Components in Nonalcoholic Fatty Liver Disease (NAFLD): What Key Messages Can Health Care Providers Offer?Nutrients · 2019Review
- Nonalcoholic Fatty Liver Disease: Lessons Learnt in the Last Five Years.Journal of clinical and experimental hepatologyArticle
- Living Donor Liver Transplant in Patients Aged 60 Years or Older: Experience from a Large Volume Centre in India.Journal of clinical and experimental hepatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of nonalcoholic fatty liver disease (NAFLD) is continuing to rise worldwide, and it is estimated that this disquieting trend will continue for another 10-15 years before prevalence begins to decrease. NAFLD is the hepatic manifestation of metabolic syndrome. As obesity, diabetes, and other lifestyle-related diseases continue to rise, the spectrum of NAFLD, e.g., nonalcoholic steatohepatitis, liver fibrosis, liver cirrhosis, liver-related morbidity, and mortality, will increase in parallel. Its widespread prevalence and associated economic burden have drawn significant attention, and a multitude of pharmaceutical companies are participating in active research trying to find a "cure". Unfortunately, as of now, no targeted treatment exists to treat this condition, and therefore, emphasis has been on its prevention. The current review focuses on the epidemiology, clinical characteristics, risk factors, and clinical outcomes of NAFLD in Western countries. It is important to understand the magnitude of NAFLD and its risk factors in Western countries where the prevalence of NAFLD has now reached epidemic proportions to identify the best strategy to prevent and possibly control this epidemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.